20240324-中邮证券-医药生物行业报告_血制品批签发平稳行业有望维持高景气度_政策有望推动院内设备更新提速_21页_1mb

Pharmaceutical and Biologic Industry Week 2024 Analysis

Market Overview

The pharmaceutical industry faces significant market risks, with a stock investment rating of "stronger than large market." The closing index point is 758,874,52, with a weekly high of 9,574,425 and low of 650,061. The industry underperformed the SSE 300 Index, declining 21.3% in the week, ranking 30th among 31 sub-sectors. Overall valuation is at historic lows, with PE (TTM) around 25.5x for biomedicine.

Key Insights and Views

Blood Products Sector

Blood product issuance remained stable in 2024, with total batches around 1,284, down due to high prior demand from the COVID-19 recovery. Long-term demand is expected to grow, driven by increased plasma supply from new collection centers and policy support for state-owned enterprises controlling the industry. Companies like Shanghai莱士 and Hualan Biologicals are recommended for their efficient operations and new product introductions.

Equipment Update Policy

The national "Action Plan for Large-Scale Equipment Update and Consumer Goods Replacement," dated March 13, 2024, aims to boost equipment investment by over 25% by 2027. This policy is expected to accelerate updates of high-end medical devices like PET/CT, PET/MR, and surgical robots, enhancing healthcare capabilities, especially in primary care settings. It could expand the market for domestic manufacturers like Mindray and LIUREN Medical.

Sector Performance

The pharmaceutical sub-sectors saw mixed results: diagnostics rose 1.5%, while pharmacy, hospital, and blood product sectors declined significantly. Despite short-term volatility, the sector offers long-term opportunities in刚需-driven areas like diagnostics, retail pharmacies, and blood products, supported by fiscal policies and export potential.

Investment Recommendations

Recommended Stocks: Sino Biological, Micro-Pulse, Piling Biological, Shanghai莱士, Meilun Health, International Medical, Kangnian药业.
Beneficiary Stocks: Linghui Medical, Minzu Medical, Sixin Ultrasound, Harbin Sense, Haijiayin Healthcare, Runmo Medical, Santai Medical, Medtronic Pharmaceutical, Miapu Healthcare, Yingnovo Technology, Taifang Drug, Dasheng Pharmaceutical, Zolo Pharmaceutical, Tianli Pharmaceutical, Yaxin Pharmaceutical, Da-Sheng Pharmaceutical, Runtian Pharmaceutical, Hua Yuan Pharmaceutical, Tian Shihong Pharmaceutical, Jin川药业, Kang Neng Pharmaceutical, Tian Di'er Pharmaceutical, Baotai Pharmaceutical, etc. Specific rankings and details available upon request.

Risks and Disclaimers

Potential risks include policy execution delays, regulatory changes, and industry-specific black swan events. All analysis should be reviewed with the accompanying免责声明 for further disclosures.